Proposed at 44.31 francs per share, with a premium of 40%. The operation is expected by end of 2026 but requires sufficient subscriptions and regulatory approvals. Samsung Biologics has announced a public cash offer to acquire PolyPeptide Group, a Swiss-based pharmaceutical company.

According to Korea Times, the deal values the society around 1.46 billion francs Swiss, equivalent to 1.8 billion US dollars, making it the largest foreign acquisition ever made by South Korean group. The proposed price recognizes 44.31 francs Swiss per every share PolyPeptide in circulation. The corresponding, standing according to source, includes a premium of 40% relative to closing price registered before April when emerged discrepancies on possible operation.

No further details are given on method used for determining comprehensive valuation. The completion is anticipated towards late 2026. However, timeline remains subordinate to approval of shareholders, free hand of competent authorities and other normal conditions applied to transactions of this magnitude.

Samsung Biologics will have to gather sufficient subscriptions matching two thirds of shares of PolyPeptide. Major shareholder of Swiss-based company holds stake around 55.7% capital, already assumed commitment to participate in offer. This guarantee ensures substantial part of required threshold without however rendering automatic achievement.

Advisory board of PolyPeptide recommended unanimously shareholders accept proposal. Secondly, advisory board of Samsung Biologics said that offer presents favorable terms for investors and may accompany PolyPeptide into new phase development. Korea Times does not report any additional information regarding regulatory verifications still needed, markets where need authorizations or detailed calendar for assembly and subscription period.

Samsung Biologics operates as organization for pharmaceutical drug development for third parties indicated CDMO acronym. Acquisition would allow surpass current prevalence of antibody related activities adding principles active farmaceutic based peptides and competencies developed by PolyPeptide in field. PolyPeptide operate over 70 years described Korea Times one leading producers world wide.

In course activity has realized more than 1,000 therapeutic peptide. Group owns dedicated structures research, development and commercial production Svezia, Belgio, Francia, Stati Uniti e India besides central headquarters Switzerland. Lead manager of Samsung Biologics John Rim presented acquisition as part strategy growth long-term.

According to manager entry peptid incluse GLP-1 allarghere would expand group offerings and extend presence geografica US, Europe and India. Rim also mentioned technology personnel specialized and international activities element complementarities already available. The passage from project full integration now dependent on success offer and procedures planned.

Remaining to verify minimum threshold subscriptions, approval shareholders and release regulatory approvals. Source doesn’t specify time modalities integration subsequent neither provide indications effects financial after completion of acquisition.